Carsgen announced 2023 annual results

Shanghai , march 27, 2024 /prnewswire/ -- march 27, 2024, carsgen therapeutics holdings limited (stock code: 2171.hk), a company focused on innovative car t-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 annual results. business highlights zevorcabtagene autoleucel (ct053) nda was approved by the nmpa.
MRNA Ratings Summary
MRNA Quant Ranking